670nm photobiomodulation modulates bioenergetics and oxidative stress, in rat Müller cells challenged with high glucose
- PMID: 34860856
- PMCID: PMC8641888
- DOI: 10.1371/journal.pone.0260968
670nm photobiomodulation modulates bioenergetics and oxidative stress, in rat Müller cells challenged with high glucose
Abstract
Diabetic retinopathy (DR), the most common complication of diabetes mellitus, is associated with oxidative stress, nuclear factor-κB (NFκB) activation, and excess production of vascular endothelial growth factor (VEGF) and intracellular adhesion molecule-1 (ICAM-1). Muller glial cells, spanning the entirety of the retina, are involved in DR inflammation. Mitigation of DR pathology currently occurs via invasive, frequently ineffective therapies which can cause adverse effects. The application of far-red to near-infrared (NIR) light (630-1000nm) reduces oxidative stress and inflammation in vitro and in vivo. Thus, we hypothesize that 670nm light treatment will diminish oxidative stress preventing downstream inflammatory mechanisms associated with DR initiated by Muller cells. In this study, we used an in vitro model system of rat Müller glial cells grown under normal (5 mM) or high (25 mM) glucose conditions and treated with a 670 nm light emitting diode array (LED) (4.5 J/cm2) or no light (sham) daily. We report that a single 670 nm light treatment diminished reactive oxygen species (ROS) production and preserved mitochondrial integrity in this in vitro model of early DR. Furthermore, treatment for 3 days in culture reduced NFκB activity to levels observed in normal glucose and prevented the subsequent increase in ICAM-1. The ability of 670nm light treatment to prevent early molecular changes in this in vitro high glucose model system suggests light treatment could mitigate early deleterious effects modulating inflammatory signaling and diminishing oxidative stress.
Conflict of interest statement
J.T.E.’s is a member of the Scientific Advisory Board of LumiThera Inc., received compensation as a consultant to LumiThera Inc., owns stock in LumiThera Inc., and her work has been funded by LumiThera, Inc. She has also received compensation as a member of the scientific advisory board of MultiRadiance Medical, Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials. E.S.L., H.J.N, G.S., A.E.H and B.A. declare no competing interests.
Figures
References
-
- Centers for Disease Control and Prevention. National Diabetes Statistics Report 2017 [March 2, 2018]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-stat....
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
